Past, present, and future therapies for Clostridium difficile-associated disease (Q36674768)

15 August 2017

1 reference

title

Past, present, and future therapies for Clostridium difficile-associated disease (English)

1 reference

15 August 2017

main subject

Clostridium difficile

0 references

author name string

Dorothy Surowiec

1

1 reference

15 August 2017

Arpi G Kuyumjian

2

1 reference

15 August 2017

Michael A Wynd

3

1 reference

15 August 2017

Cristina E Cicogna

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

5 December 2006

1 reference

Annals of Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

40

1 reference

15 August 2017

issue

12

1 reference

15 August 2017

page(s)

2155-2163

1 reference

Clostridium difficile-associated diarrhea in adults

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Treatment of Clostridium difficile-associated disease: old therapies and new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Metronidazole for Clostridium difficile-associated disease: is it okay for Mom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

An epidemic, toxin gene-variant strain of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Clinical manifestations, treatment and control of infections caused by Clostridium difficile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Fluoroquinolone use and Clostridium difficile-associated diarrhea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Clostridium difficile infection in patients with unexplained leukocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Cytotoxicity Assay in Antibiotic-Associated Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of Premier Cytoclone A+B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

How to detect Clostridium difficile variant strains in a routine laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Diagnosis and treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Factors associated with failure of metronidazole in Clostridium difficile-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Intracolonic use of vancomycin for treatment of clostridium difficile colitis in a patient with a diverted colon: report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Intravenous metronidazole for the treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Comparison of the in vitro activities of teicoplanin and vancomycin against Clostridium difficile and their interactions with cholestyramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Recurrent Clostridium difficile-associated colitis responding to cholestyramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Intravenous immunoglobulin for resistant Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

In vitro and in vivo activities of nitazoxanide against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Nitazoxanide for the treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Successful treatment with rifampin for fulminant antibiotics-associated colitis in a patient with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Guideline for Hand Hygiene in Health-Care Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Rapid detection of toxigenic Clostridium difficile from stool samples by a nested PCR of toxin B gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1H332

21 January 2018

Identifiers

DOI

10.1345/APH.1H332

1 reference

15 August 2017

1 reference